Replies to post #654579 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

The submission stuff belongs to LP's domain. Whatever she decides to do suits the best interest of investors. She is the one who has spent one third or one half of her professional life bringing this revolution from concept into reality. She deserves the trust from the longs. BTW, Cofer Black only gave her briefings. So LP has the whole picture not the outsiders.

On another note, have you realized the significance of the following figure? I don't mean to brag. Am I the first one on this board who correlated the figure from ASCO present with the p3 trial? You may think all my other dot connecting stuff is probabilistic though you may prefer to call it BS which is fine with me. But the figure and the data are deterministic. They don't lie. It should get you full attention.



This figure is about expansion of T cell receptor (TCR) clones, one of key measures adopted in the combo trial.

The higher number of total TCR clonal expansion indicates better immune response.

According to my investigation, there are only four trials which adopted it as a measure. Two were terminated. Only the following two were finished. The first one is important since it was sponsored by NCI. Can you see from the publication that they had T cell expansion like the one from p3 trial? Absolutely no. As a matter of fact, from the conclusion, we can see there is no statistical difference between the two arms. Keep in mind in p3 trial, the patients had to receive SOC which was harmful for immune response according to the lead study author Dmitriy Zamarin, MD PhD, Director of Translational Research at Memorial Sloan Kettering Cancer Center.

Now can you still see the light?

In addition to the favorable results discovered in this data, it is also crucial to note that there was an early decrease in T-cell receptor diversity and potential killing of tumor-associated T-cell receptor clones with concurrent chemoradiation, which could imply harmful consequences for immune response. This information warrants further clinical studies navigating differential sequencing of chemoradiation and immune checkpoint [inhibitors]

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT03738228

https://ascopost.com/news/march-2023/atezolizumab-may-be-an-effective-primer-for-chemoradiation-in-patients-with-locally-advanced-cervical-cancer/



VB-111 in Surgically Accessible Recurrent/Progressive GBM
https://classic.clinicaltrials.gov/ct2/show/NCT04406272
Principal Investigator: Patrick Wen, MD Dana-Farber Cancer Institute